This cross-sectional study included outpatients aged ≥ 12 years with an asthma diagnosis (ICD-10: J45, J46) who had received ≥ 1 SABA (European Pharmaceutical Market Research Association [EphMRA] ATC: R03A4) prescription(s) between July 2017 and June 2018 in 924 general physician and 22 pneumologist (PN) practices. Furthermore, patients had to fulfill the observability criterion of having had at least two physician visits (not necessarily asthma-related) during the study period. Patients with chronic obstructive pulmonary disease in addition to their asthma diagnosis were excluded from the study (Fig. 1).

Selection of study patients. COPD chronic obstructive pulmonary disease, GINA Global Initiative for Asthma, ICD-10 International Classification of Diseases, 10th Revision. A small percentage of patients received medications that could not be categorized into one of the five GINA stages